

CURRICULUM VITAE
The Johns Hopkins University School of Medicine

Christian Paul PAVLOVICH

March 31, 2020

DEMOGRAPHIC AND PERSONAL INFORMATION

Current Appointments:

Johns Hopkins Bayview Medical Center, Baltimore, MD.
Johns Hopkins Hospital, Baltimore, MD.

Personal Data:

Office: James Buchanan Brady Urological Institute
Department of Urology
301 Building, Suite 3200
Johns Hopkins Bayview Medical Center
4940 Eastern Avenue
Baltimore, MD 21224
Tel: (410) 550-0013 / voicemail (410) 550-3340
Fax: (410) 550-4188
Email: cpavlov2@jhmi.edu

h-index: 39 (January 2020, *Scopus*)

Education and Training:

1984-87	A.B.	<i>Biology</i> , Harvard University, Cambridge, MA, <i>cum laude</i>
1987-88	B.S.	<i>Molecular Biology</i> , Université de Genève, Switzerland (“Certificat” Awarded in 1992)
1990-91	Certificate	<i>Immunology</i> , HHMI-NIH Research Program, Bethesda, MD
1988-93	M.D.	University of California, San Francisco, CA, <i>cum laude</i>
1993-95	Intern & Resident	<i>General Surgery</i> , New York Hospital-Cornell Medical Ctr., NY
1995-99	Resident	<i>Urology</i> , New York Hospital-Cornell Medical Ctr., NY
1999-01	Fellow	<i>Urologic Oncology</i> , National Cancer Institute, Bethesda, MD

Professional Experience:

2001 - 2005	Assistant Professor, Urology, Johns Hopkins University School of Medicine
2001 - 2005	Special Volunteer, Urologic Oncology Branch, Warren G. Magnuson Clinical Center, National Institutes of Health
2001 - Present	Director of Urologic Oncology, Johns Hopkins Bayview Medical Center
2005 - 2015	Associate Professor, Urology, Johns Hopkins University School of Medicine
2015 – Present	Professor, Urology and Oncology, Johns Hopkins University School of Medicine

RESEARCH ACTIVITIES**Publications:**

Peer-reviewed original science research:

- 1) **Pavlovich CP**, Schlegel PN. Fertility options after vasectomy: A cost-effectiveness analysis. *Fertility and Sterility* 1997; 67(1): 133-141.
- 2) Schlegel PN, **Pavlovich CP**. Male infertility treatment options: A cost-effectiveness analysis. *J Clin Outcomes Med* 1997; 4 (6): 27-32.
- 3) Kavolius JP, Mastorakos DP, **Pavlovich CP**, Russo P, Burt ME, Brady MS. Resection of metastatic renal cell carcinoma. *J Clin Oncol* 1998; 16 (6): 2261-2266.
- 4) Poppas DP, **Pavlovich CP**, Folkman J, Voest EE, Chen X, Luster AD, and O'Donnell MA. Intravesical BCG induces the anti-angiogenic chemokine IP-10. *Urology* 1998; 52 (2): 268-276.
- 5) **Pavlovich CP**, Gmyrek GA, Gardner TA, Poppas DP, Mininberg DT. Flexible transinguinal laparoscopy to assess the contralateral ring in pediatric inguinal hernias. *Tech Urol* 1998; 4 (3): 141-144.
- 6) Ravizzini PI, Shulsinger D, Guarnizo E, **Pavlovich CP**, Marion D, Sosa RE. Hand-assisted laparoscopic donor nephrectomy versus standard laparoscopic donor nephrectomy: a comparison study in the canine model. *Tech Urol* 1999; 5 (3): 174-178.
- 7) Guarnizo EG, **Pavlovich CP**, Seiba M, Carlson DL, Vaughan ED Jr., Sosa RE. Ureteroscopic biopsy of upper tract urothelial carcinoma: improved diagnostic accuracy and histopathologic considerations using a multi-biopsy approach. *J Urol* 2000; 163: 52-55.
- 8) **Pavlovich CP**, Kråling BM, Stewart RJ, Bochner BH, Chen X, Luster AD, Poppas DP, O'Donnell MA. BCG-induced urinary cytokines inhibit microvascular endothelial cell proliferation. *J Urol* 2000; 163 (6): 2014-21.
- 9) Terrence K, **Pavlovich CP***, Matechak EO, Fowlkes BJ. Premature expression of TCR $\gamma\delta$ suppresses TCR $\alpha\beta$ gene rearrangement but permits development of $\gamma\delta$ lineage T cells. *J Exp Med* 2000; 192 (4): 1-13. *joint first authorship
- 10) Choyke PL, **Pavlovich CP**, Daryanni K, Hewitt SM, Linehan WM, Walther MM. Intraoperative ultrasound during renal parenchymal sparing surgery for hereditary renal cancers: a 10-year experience. *J Urol* 2001; 165: 397-400.
- 11) **Pavlovich CP**, King P, Goldstein M, Schlegel PN. Evidence of a treatable endocrinopathy in infertile men. *J Urol* 2001; 165: 837-841.
- 12) Schmidt LS, Warren MB, Nickerson ML, Weirich G, Matrosova V, Toro JR, Turner ML, Duray P, Merino M, Hewitt S, **Pavlovich CP**, Glenn G, Greenberg CR, Linehan WM, Zbar B. Birt-Hogg-Dubé syndrome, a genodermatosis associated with spontaneous pneumothorax and kidney neoplasia, maps to chromosome 17p11.2. *Am J Hum Genet* 2001; 69(4): 876-82.
- 13) Pautler SE, **Pavlovich CP**, Mikityansky I, Drachenberg DE, Choyke PL, Linehan WM, Wood BJ, Walther MM. Retroperitoneoscopic-guided radiofrequency ablation of renal tumors. *Can J Urol* 2001; 8(4): 1330-3.
- 14) Phillips JL, Hayward SW, Wang, Y, Vasselli J, **Pavlovich CP**, Padilla-Nash H, Pezullo JR, Ghadimi BM, Grossfeld GD, Rivera A, Linehan WM, Cunha GR, Ried T. The consequences of chromosomal aneuploidy on gene expression profiles in a cell line model for prostate carcinogenesis. *Cancer Res* 2001; 61(22): 8143-9.
- 15) **Pavlovich CP**, Walther MM, Choyke PL, Pautler SE, Chang R, Linehan WM, Wood BJ. Percutaneous radiofrequency ablation of small renal tumors: Initial results. *J Urol* 2002; 167: 10-15.
- 16) Zbar B, Alvord WG, Glenn G, Turner M, Toro J, **Pavlovich CP**, Merino M, Linehan WM. Risk of renal and colonic neoplasms and spontaneous pneumothorax in the Birt-Hogg-Dubé syndrome. *Cancer Epidemiol Biomarkers Prev* 2002; 11(4): 393-400.

- 17) Nickerson ML, Warren MB, Toro JR, Matrosova V, Glenn G, Turner ML, Duray P, Merino M, Choyke P, **Pavlovich CP**, Sharma N, Walther M, Munroe D, Hill R, Maher E, Greenberg C, Lerman MI, Linehan WM, Zbar B, Schmidt LS. Mutations in a novel gene lead to kidney tumors, lung wall defects and benign tumors of the hair follicle in patients with the Birt-Hogg-Dubé syndrome. *Cancer Cell* 2002; 2(2):157-164.
- 18) Pautler SE, Choyke PL, **Pavlovich CP**, Daryanani K, Walther MM. Intraoperative ultrasound aids in dissection during laparoscopic partial adrenalectomy. *J Urol* 2002; 168(4 Pt 1):1352-5.
- 19) Hwang JJ, Uchio EM, **Pavlovich CP**, Pautler SE, Libutti SK, Linehan WM, Walther MM. Surgical management of multi-organ visceral tumors in patients with von Hippel-Lindau disease: a single stage approach. *J Urol* 2003; 169: 895-8.
- 20) Bhayani SB, **Pavlovich CP**, Hsu TS, Sullivan W, Su LM. Prospective Comparison of Short Term Convalescence: Laparoscopic Radical Prostatectomy versus Open Radical Prostatectomy. *Urology* 2003; 61: 612-616.
- 21) **Pavlovich CP**, Linehan WM, Eyster R, Walther MM, Zbar B, Hewitt SE, Merino MJ. Renal tumors in the Birt-Hogg-Dubé syndrome. *Am J Surg Path* 2002; 26: 1542-52.
- 22) **Pavlovich CP**, Padilla-Nash H, Wangsa D, Nickerson ML, Matrosova V, Linehan WM, Ried T, Phillips JL. Patterns of aneuploidy in advanced renal cell carcinoma. *Genes Chromosomes Cancer* 2003; 37(3): 252-60.
- 23) Gonzalgo ML, **Pavlovich CP**, Lee SM, Nelson WG. Prostate cancer detection by GSTP1 methylation analysis of post-biopsy urine specimens. *Clin Cancer Res* 2003; 9(7): 2673-7.
- 24) Bhayani SB, **Pavlovich CP**, Strup SE, Dahl, DM, Landman J, Fabrizio MD, Sundaram CP, Kaouk J, and Su LM. Laparoscopic radical prostatectomy: a multi-institutional study of conversion to open surgery. *Urology* 2004; 63, 99-102.
- 25) Link RE, Su LM, Bhayani SB, **Pavlovich CP**. Making ends meet: a cost comparison of laparoscopic and open radical retropubic prostatectomy. *J Urol* 2004; 172: 269-74.
- 26) Bhayani SB, **Pavlovich CP**, Su LM. Use of a specialized prostatic urethral sound to facilitate nerve-sparing laparoscopic radical prostatectomy. *J Endourol* 2004; 18: 289-291.
- 27) Su LM, Link RE, Bhayani SB, Sullivan W, **Pavlovich CP**. Nerve-sparing laparoscopic radical prostatectomy: replicating the open surgical technique. *Urology* 2004; 64:123-7.
- 28) Rogers CG, Yan G, Zha S, Gonzalgo ML, Isaacs WB, Luo J, DeMarzo AM, Nelson WG, **Pavlovich CP**. Prostate cancer detection by urinalysis for alpha methylacyl CoA racemase protein. *J Urol* 2004; 172:1501-1503.
- 29) Gonzalgo ML, Yan G, Rogers CG, Nelson WG, **Pavlovich CP**. Molecular profiling and classification of sporadic renal cell carcinoma by quantitative methylation analysis. *Clin Cancer Res* 2004; 10: 7276-83.
- 30) Link RE, Su LM, Sullivan W, Bhayani SB, **Pavlovich CP**. Health related quality of life before and after laparoscopic radical prostatectomy. *J Urol* 2005; 173: 175-179.
- 31) **Pavlovich CP**, Grubb RL 3rd*, Hurley K, Glenn GM, Toro J, Schmidt LS, Torres-Cabala C, Merino MJ, Zbar B, Choyke P, Walther MM, Linehan WM. Evaluation and Management of Renal Tumors in the Birt-Hogg-Dubé Syndrome. *J Urol* 2005; 173:1482-1486. *joint first authorship
- 32) Gonzalgo ML, **Pavlovich CP**, Trock BJ, Link RE, Sullivan W, Su L-M. Classification and trends of perioperative morbidities following laparoscopic radical prostatectomy. *J Urol* 2005; 174:135-9.
- 33) Wagner A, Link R, **Pavlovich C**, Sullivan W, Su L. Use of a validated quality of life questionnaire to assess sexual function following laparoscopic radical prostatectomy. *Int J Impot Res* 2006; 18 (1): 69-76.
- 34) Vocke CD, Yang Y, **Pavlovich CP**, Schmidt LS, Nickerson ML, Torres-Cabala CA, Merino MJ, Walther MM, Zbar B, Linehan WM. High Frequency of Somatic Frameshift BHD Gene

- Mutations in Birt-Hogg-Dubé-Associated Renal Tumors. *J Natl Cancer Inst* 2005; 97(12):931-5.
- 35) Markushin Y, Gaikwad N, Zhang H, Kapke P, Rogan EG, Cavalieri EL, Trock BJ, **Pavlovich C**, Jankowiak R. Potential biomarker for early risk assessment of prostate cancer. *Prostate* 2006; 66(14): 1565-71.
 - 36) Rogers CG, Gonzalgo ML, Yan G, Bastian PJ, Chan DY, Nelson WG, **Pavlovich CP**. High concordance of gene methylation in post-digital rectal examination and post-biopsy urine samples for prostate cancer detection. *J Urol* 2006; 176 (5): 2280-2284.
 - 37) Rogers CG, Su LM, Link RE, Sullivan W, Wagner A, **Pavlovich CP**. Age-stratified functional outcomes after Laparoscopic Radical Prostatectomy. *J Urol* 2006; 176 (6): 2448-2252.
 - 38) Permpongkosol S, Link RE, Su LM, Romero FR, Bagga HS, **Pavlovich CP**, Jarrett TW, Kavoussi LR. Complications of 2,775 Urologic Laparoscopic Procedures: 1993-2005. *J Urol* 2007; 177(2): 580-85.
 - 39) Muntener M, Nielsen ME, Romero FR, Schaeffer EM, Allaf ME, Brito FA, **Pavlovich CP**, Kavoussi LR, Jarrett TW. Long-Term Oncologic Outcome after Laparoscopic Radical Nephroureterectomy for Upper Tract Transitional Cell Carcinoma. *Eur Urol* 2007; 51(6): 1482-4.
 - 40) Wagner AA, Link RE, Trock BJ, Sullivan W, **Pavlovich CP**. Comparison of Open and Laparoscopic Radical Prostatectomy Outcomes from a Surgeon's Early Experience. *Urology* 2007; 70(4):667-71.
 - 41) Muntener M, Schaeffer EM, Romero FR, Nielsen ME, Allaf ME, Brito FA, **Pavlovich CP**, Kavoussi LR, Jarrett TW. Incidence of local recurrence and port site metastasis after laparoscopic radical nephroureterectomy. *Urology* 2007; 70(5):864-868.
 - 42) Yang Y, Padilla-Nash HM, Vira MA, Abu-Asab MS, Val D, Worrell R, Tsokos M, Merino MJ, **Pavlovich CP**, Ried T, Linehan WM, Vocke CD. The UOK 257 cell line: a novel model for studies of the human Birt-Hogg-Dubé gene pathway. *Cancer Genet Cytogenet* 2008; 180(2):100-109.
 - 43) **Pavlovich CP**, Trock BJ, Sulman A, Wagner AA, Mettee LZ, Su LM. Three Year Actuarial Biochemical Recurrence-Free Survival Following Laparoscopic Radical Prostatectomy: Experience from a Tertiary Referral Center in the United States. *J Urol* 2008; 179(3): 917-922.
 - 44) Levinson AW, **Pavlovich CP**, Ward NT, Link RE, Mettee LZ, Su LM. Association of Surgeon Subjective Characterization of Nerve Sparing Quality with Potency Following Laparoscopic Radical Prostatectomy. *J Urol* 2008; 179(4):1510-1514.
 - 45) Levinson AW, Bagga HS, **Pavlovich CP**, Mettee LZ, Ward NT, Link RE, Su LM. The Impact of Prostate Size on Urinary Quality of Life Indexes Following Laparoscopic Radical Prostatectomy. *J Urol* 2008; 179(5):1818-1822.
 - 46) Bivalacqua TJ, Schaeffer EM, Alphs H, Mettee L, Wagner AA, Su LM, **Pavlovich CP**. Intraperitoneal Effects of Extraperitoneal Laparoscopic Radical Prostatectomy. *Urology* 2008; 72(2):273-277.
 - 47) Fujita K, Ewing CM, Sokoll LJ, Elliott DJ, Cunningham M, De Marzo AM, Isaacs WB, **Pavlovich CP**. Cytokine Profiling of Prostatic Fluid From Cancerous Prostate Glands Identifies Cytokines Associated with Extent of Tumor and Inflammation. *Prostate* 2008; 68(8):872-882.
 - 48) Richstone L, Seideman C, Baldinger L, Permpongkosol S, Jarrett TW, Su LM, **Pavlovich C**, Kavoussi LR. Conversion During Laparoscopic Surgery: Frequency, Indications and Risk Factors. *J Urol* 2008; 180(3):855-859.
 - 49) Fujita K, Ewing CM, Chan DYS, Mangold LA, Partin AW, Isaacs WB, **Pavlovich CP**. Endoglin (CD105) as a Urinary and Serum Marker of Prostate Cancer. *Int J Cancer* 2009; 124(3):664-669.

- 50) Guzzo TJ, Allaf ME, Pierorazio PM, Miller D, McNeil BK, Kavoussi LR, **Pavlovich CP**, Schaeffer EM. Perioperative Outcomes of Elderly Patients Undergoing Laparoscopic Renal Procedures. *Urology* 2009; 73(3): 572-576.
- 51) Guzzo TJ, Schaeffer EM, McNeil BK, Pollock RA, **Pavlovich CP**, Allaf ME. Laparoscopic radical nephrectomy for patients with pathologic T3b Renal-cell carcinoma: The Johns Hopkins Experience. *J Endourol* 2009; 23(1): 63-68.
- 52) Levinson AW, Ward NT, Sulman A, Mettee LZ, Link RE, Su LM, **Pavlovich CP**. The impact of prostate size on perioperative outcomes in a large laparoscopic radical prostatectomy series. *J Endourol* 2009; 23(1): 147-152.
- 53) Fujita K, **Pavlovich CP**, Netto GJ, Konishi Y, Isaacs WB, Ali S, De Marzo A, Meeker AK. Specific detection of prostate cancer cells in urine by multiplex immunofluorescence cytology. *Hum Pathol* 2009; 40 (7): 924-933.
- 54) Albadine R, Wang W, Brownlee NA, Toubaji A, Billis A, Argani P, Epstein JI, Garvin AJ, Cousi R, Schaeffer EM, **Pavlovich C**, Netto GJ. Topoisomerase II alpha Status in Renal Medullary Carcinoma: Immuno-Expression and Gene Copy Alterations of a Potential Target of Therapy. *J Urol* 2009; 182(2):735-40.
- 55) Fujita K, Landis P, McNeil BK, **Pavlovich CP**. Serial Prostate Biopsies are Associated with an Increased Risk of Erectile Dysfunction. *J Urol* 2009; 182(6):2664-9.
- 56) Fujita K, Ewing CM, Getzenberg RH, Parsons JK, Isaacs WB, **Pavlovich CP**. Monocyte chemotactic protein-1 (MCP-1/CCL-2) is associated with prostatic growth dysregulation and benign prostatic hyperplasia. *Prostate* 2010;70(5):473-81.
- 57) Schaeffer EM, Guzzo TJ, Furge KA, Netto G, Westphal M, Dykema K, Yang XJ, Zhou M, The BT, **Pavlovich CP**. Renal medullary carcinoma: Molecular, pathologic and clinical evidence for treatment with topoisomerase inhibiting therapy. *BJU Int* 2010; 106(1): 62-5.
- 58) Levinson AW, Ward NT, Sanda MG, Mettee LZ, Wei JT, Su LM, Litwin MS, **Pavlovich CP**. Comparison of validated instruments measuring sexual function in men. *Urology* 2010; 76(2): 380-6.
- 59) Secin FP, Savage C, Abbou C (list shortened)..., **Pavlovich CP**, Levinson AW, Touijer KA, Vickers A, Guillonneau B. The learning curve for laparoscopic radical prostatectomy: An international multicenter study. *J Urol* 2010;184(6):2291-6.
- 60) Magheli A, Gonzalgo ML, Su LM, Guzzo TJ, Netto G, Humphreys EB, Han M, Partin AW, **Pavlovich CP***: Impact of surgical technique (open vs laparoscopic vs robotic-assisted) on pathological and biochemical outcomes following radical prostatectomy: an analysis using propensity score matching. *BJU Int* 2011; 107(12): 1956-62. *BJUI Coffey-Krane Award-winning paper
- 61) Fujita K, Ewing CM, Isaacs WB, **Pavlovich CP**. Immunomodulatory IL-18 binding protein is produced by prostate cancer cells and its levels in urine and serum correlate with tumor status. *Int J Cancer* 2011; 29(2): 424-32.
- 62) Levinson AW, Lavery HJ, Ward NT, Su LM, **Pavlovich CP**: Is a return to baseline sexual function possible? An analysis of sexual function outcomes following laparoscopic radical prostatectomy. *World J Urol* 2011; 29(1); 29-34.
- 63) Ward NT, Parsons JK, Levinson AW, Bagga HS, Mettee LZ, Su LM, **Pavlovich CP**: Prostate size is not associated with recovery of sexual function after laparoscopic radical prostatectomy. *Urology* 2011; 77(4): 952-6.
- 64) Lin BM, Hyndman ME, Steele KE, Feng Z, Trock BJ, Schweitzer MA, **Pavlovich CP**: Incidence and Risk Factors for Inguinal and Incisional Hernia After Laparoscopic Radical Prostatectomy. *Urology* 2011; 77(4): 957-62.
- 65) Eifler JB, Levinson AW, Hyndman ME, Trock BJ, **Pavlovich CP**: Pelvic Lymph Node Dissection is Associated With Symptomatic Venous Thromboembolism Risk During Laparoscopic Radical Prostatectomy. *J Urol* 2011; 185(5): 1661-65.

- 66) Mullins JK, Hyndman ME, Mettee LZ, **Pavlovich CP**: Comparison of extraperitoneal and transperitoneal pelvic lymph node dissection during minimally invasive radical prostatectomy. *J Endourol* 2011; 25(12):1883-7.
- 67) Albadine R, Hyndman ME, Chaux A, Jeong JY, Saab S, Tavora F, Epstein JI, Gonzalgo ML, **Pavlovich CP**, Netto GJ: Characteristics of positive surgical margins in robotic-assisted radical prostatectomy, open retropubic radical prostatectomy, and laparoscopic radical prostatectomy: a comparative histopathologic study from a single academic center. *Hum Pathol* 2012; 43(2):254-60.
- 68) Calenda G, Strong TD, **Pavlovich CP**, Schaeffer EM, Burnett AL, Yu W, Davies KP, Bivalacqua TJ: Whole genome microarray of the major pelvic ganglion after cavernous nerve injury: new insights into molecular profile changes after nerve injury. *BJU Int* 2012; 109(10): 1552-64.
- 69) Pierorazio PM, Ross AE, Lin BM, Epstein JI, Han M, Walsh PC, Partin AW, **Pavlovich CP**, Schaeffer EM: Preoperative characteristics of high-Gleason disease predictive of favourable pathological and clinical outcomes at radical prostatectomy. *BJU Int* 2012; 110(8); 1122-8.
- 70) Li J, Zhang ZH, Yin CJ, **Pavlovich C**, Luo J, Getzenberg R, Zhang W: Effect of surgical procedures on prostate tumor gene expression profiles. *Asian J Androl* 2012; 14(5); 708-714.
- 71) Pierorazio PM, Lin BM, Mullins JK, Hyndman ME, Schaeffer EM, Han M, Partin AW, **Pavlovich CP**: Preoperative characteristics of men with unfavorable high-Gleason prostate cancer at radical prostatectomy. *Urol Oncol* 2013; 31(5);589-94.
- 72) Pierorazio PM, Mullins JK, Eifler JB, Voth K, Hyams ES, Han M, **Pavlovich CP**, Bivalacqua TJ, Partin AW, Allaf ME, Schaeffer EM: Contemporaneous comparison of open vs minimally-invasive radical prostatectomy for high-risk prostate cancer. *BJU Int* 2013; 112(6) 751-7.
- 73) Pierorazio PM, Mullins JK, Ross AE, Hyams ES, Partin AW, Han M, Walsh PC, Schaeffer EM, **Pavlovich CP**, Allaf ME, Bivalacqua TJ: Trends in immediate perioperative morbidity and delay in discharge after open and minimally invasive radical prostatectomy (RP): a 20-year institutional experience. *BJU Int.* 2013;112(1):45-53.
- 74) Sundi D, Reese AC, Mettee LZ, Trock BJ, **Pavlovich CP**: Laparoscopic and robotic radical prostatectomy outcomes in obese and extremely obese men. *Urology* 2013; 82(3), 600-605.
- 75) **Pavlovich CP**, Levinson AW, Su L-M, Mettee LZ, Feng Z, Bivalacqua TJ, Trock BJ: Nightly vs. on-demand sildenafil for penile rehabilitation after minimally-invasive nerve-sparing radical prostatectomy: Results of a randomized double-blind trial with placebo. *BJU Int* 2013;112(6):844-51.
- 76) Kaye DR, Hyndman ME, Segal RL, Mettee LZ, Trock BJ, Feng Z, Su L-M, Bivalacqua TJ, **Pavlovich CP**: Urinary outcomes are significantly affected by nerve-sparing quality during radical prostatectomy. *Urology* 2013; 82(6), 1348-54.
- 77) **Pavlovich CP**, Cornish TC, Mullins JK, Fradin J, Mettee LZ, Connor JT, Reese AC, Askin FB, Luck R, Epstein JI, Burke HB: High-resolution transrectal ultrasound: Pilot study of a novel technique for imaging clinically localized prostate cancer. *Urol Oncol.* 2014; 32(1): 34.e27-32.
- 78) Reese AC, Johnson PT, Gorin MA, Pierorazio PM, Allaf ME, Fishman EK, Netto GJ, **Pavlovich CP**: Pathological Characteristics and Radiographic Correlates of Complex Renal Cysts. *Urol Oncol.* 2014; 32(7): 1010-1016.
- 79) Ball MW, Bezerra SM, Gorin MA, Cowan M, **Pavlovich CP**, Pierorazio PM, Netto GJ, Allaf ME. Grade Heterogeneity in Small Renal Masses: Potential Implications for Renal Mass Biopsy. *J Urol.* 2015; 193(1): 36-40.
- 80) Ball MW, Reese AC, Mettee L, **Pavlovich CP**: Safety of Minimally Invasive Radical Prostatectomy in Patients with Prior Abdominopelvic or Inguinal Surgery. *J Endourol.* 2015; 29(2):192-7.

- 81) Rowe SP, Gage KL, Faraj SF, Macura KJ, Cornish TC, Gonzalez-Roibon N, Guner G, Munari E, Partin AW, **Pavlovich CP**, Han M, Carter HB, Bivalacqua TJ, Blackford A, Holt D, Dannals RF, Netto GJ, Lodge MA, Mease RC, Pomper MG, Cho SY: ¹⁸F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer. *J Nucl Med* 2015; 56(7):1003-10.
- 82) Ludwig WW, Sopko NA, Azoury SC, Dhanasopon A, Mettee L, Dwarakanath A, Steele KE, Nguyen HT, **Pavlovich CP**: Inguinal hernia repair during extraperitoneal robot-assisted laparoscopic radical prostatectomy. *J Endourology* 2016; 30(20): 208-11.
- 83) Ball MW, Gorin MA, Harris KT, Curtiss KM, Netto GJ, **Pavlovich CP**, Pierorazio PM, Allaf ME: Extent of Renal Vein Invasion Influences Prognosis in Patients with Renal Cell Carcinoma. *BJU Int.* 2016; 118(1):112-7.
- 84) Gorin MA, Rowe SP, Baras AS, Solnes LB, Ball MW, Pierorazio PM, **Pavlovich CP**, Epstein JI, Javadi MS, Allaf ME: Prospective Evaluation of ^{99m}Tc-sestamibi SPECT/CT for the Diagnosis of Renal Oncocytomas and Hybrid Oncocytic/Chromophobe Tumors. *Eur Urol.* 2016; 69(3): 413-6.
- 85) Hyndman ME, Bivalacqua TJ, Feng Z, Mettee LZ, Su LM, Trock BJ, **Pavlovich CP**. Nightly sildenafil use after radical prostatectomy has adverse effects on urinary convalescence: Results from a randomized trial of nightly vs on-demand dosing regimens. *Can Urol Assoc J.* 2015 Nov-Dec; 9 (11-12):414-9. Erratum pub 2016.
- 86) Ghai S, Eure G, Fradet V, Hyndman ME, McGrath T, Wodlinger B, **Pavlovich CP**: Assessing Cancer Risk in Novel 29 MHz Micro-Ultrasound Images of the Prostate: Creation of the PRI-MUS (prostate risk identification using micro-ultrasound) protocol. *J Urol.* 2016; 196(2):562-9.
- 87) Gnanaraj J, Balakrishnan S, Umar Z, Antonarakis ES, **Pavlovich CP**, Wright SM, Khaliq W: Medical hospitalizations in prostate cancer survivors. *Med Oncol.* 2016 Jul;33(7):81.
- 88) Tosoian JJ, Chappidi M, Feng Z, Humphreys EB, Han M, **Pavlovich CP**, Epstein JI, Partin AW, Trock BJ: Prediction of Pathologic Stage Based on Clinical Stage, Serum PSA, and Biopsy Gleason Score: Partin Tables in the Contemporary Era. *BJU Int.* 2016 [Epub ahead of print].
- 89) Ghabili K, Tosoian JJ, Schaeffer EM, **Pavlovich CP**, Golzari SE, Khajir G, Andreas D, Benzon B, Vuica-Ross M, Ross AE. The History of Prostate Cancer From Antiquity: Review of Paleopathological Studies. *Urology.* 2016 97:8-12.
- 90) An JY, Ball MW, Gorin MA, Hong JJ, Johnson MH, **Pavlovich CP**, Allaf ME, Pierorazio PM. Partial vs Radical Nephrectomy for T1-T2 Renal Masses in the Elderly: Comparison of Complications, Renal Function, and Oncologic Outcomes. *Urology.* 2017 100:151-157.
- 91) Tosoian JJ, Patel HD, Mamawala M, Landis P, Wolf S, Elliott DJ, Epstein JI, Carter HB, Ross AE, Sokoll LJ, **Pavlovich CP**: Longitudinal assessment of urinary PCA3 for predicting prostate cancer grade reclassification in favorable-risk men during active surveillance. *Prostate Cancer Prostatic Dis.* 2017 Sept 20(3): 339-342.
- 92) Druskin SC, Liu JJ, Young A, Feng Z, Dianat SS, Ludwig WW, Trock BJ, Macura KJ, **Pavlovich CP**: Prostate MRI prior to radical prostatectomy: effects on nerve sparing and pathological margin status. *Res Rep Urol.* 2017 Apr 18(9):55-63.
- 93) Druskin SC, Tosoian JJ, Young A, Collica S, Srivastava A, Ghabili K, Macura KJ, Carter HB, Partin AW, Sokoll LJ, Ross AE, **Pavlovich CP**: Combining Prostate Health Index density, magnetic resonance imaging and prior negative biopsy status to improve the detection of clinically significant prostate cancer. *BJU Int.* 2018 Apr 121(4): 619-626.
- 94) Giri VN, Knudsen KE, Kelly WK... **Pavlovich CP**... and Gomella LG: Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. *J Clin Oncol.* 2018 Feb;36(4):414-424.

- 95) Li QK, **Pavlovich CP**, Zhang H, Kinsinger CR, Chan DW. Challenges and opportunities in the proteomic characterization of clear cell renal cell carcinoma (ccRCC): A critical step towards the personalized care of renal cancers. *Semin Cancer Biol.* 2019 Apr;55:8-15.
- 96) Gorgen ARH, **Pavlovich CP**: Easy, reproducible extraperitoneal pelvic access for robot - assisted radical prostatectomy. *Int Braz J Urol.* 2019 Jan-Feb;45(1):189.
- 97) Druskin SC, Mamawala M, Tosoian JJ, Epstein JI, **Pavlovich CP**, Carter HB, Trock BJ. Older Age Predicts Biopsy and Radical Prostatectomy Grade Reclassification to Aggressive Prostate Cancer in Men on Active Surveillance. *J Urol.* 2019 Jan;201(1):98-104.
- 98) Parsons JK, Pinto PA, **Pavlovich CP**, Uchio E, Kim HL, Nguyen MN, Gulley JL, Jamieson C, Hsu P, Wojtowicz M, Parnes H, Schlom J, Dahut WL, Madan RA, Donahue RN, Chow HS. A Randomized, Double-blind, Phase II Trial of PSA-TRICOM (PROSTVAC) in Patients with Localized Prostate Cancer: The Immunotherapy to Prevent Progression on Active Surveillance Study. *Eur Urol Focus.* 2018 Sep;4(5):636-638.
- 99) Faisal FA, Tosoian JJ, Han M, Macura KJ, **Pavlovich CP***, Lotan TL* (*co-senior authorship). Clinical, pathologic, and oncologic findings of radical prostatectomy patients with extraprostatic extension diagnosed on pre-operative prostate biopsy. *J Urol.* 2019 May;201(5):937-942.
- 100) Patel HD, Semerjian A, Gupta M, **Pavlovich CP**, Johnson MH, Gorin MA, Allaf ME, Pierorazio PM. Surgical removal of renal tumors with low metastatic potential based on clinical radiographic size: A systematic review of the literature. *Urol Oncol.* 2019 Aug; 37(8):519-524.
- 101) Koo K, Faisal F, Gupta N et al: Promoting Opioid Stewardship in Endourology Work Group. *J Urol* 2020 Jan; 203(1): 151-158.
- 102) Patel HD, Faisal FA, Patel ND, **Pavlovich CP**, Allaf ME, Han M, Herati AS. Effect of a Prospective Opioid Reduction Intervention on Opioid Prescribing and Use after Radical Prostatectomy: Results of the ORIOLES Initiative. *BJU Int.* 2019 Oct 23. doi: 10.1111/bju.14932. [Epub ahead of print]
- 103) Clark DJ, Dhanasekaran SM, Petralia F, ..., **Pavlovich CP**,... Zhang H; Clinical Proteomic Tumor Analysis Consortium. Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma. *Cell.* 2019 Oct 31;179(4):964-983
- 104) Su ZT, Patel HD, Epstein JI, **Pavlovich CP**, Allaf ME. Downgrading of grade group 2 intermediate-risk prostate cancer from biopsy to radical prostatectomy: Comparison of outcomes and predictors to identify potential candidates for active surveillance. *Cancer.* 2020 Apr 15;126(8):1632-1639.
- 105) Lee B, Mahmud I, Marchica J, Dereziński P, Qi F, Wang F, Joshi P, Valerio F, Rivera I, Patel V, **Pavlovich CP**, Garrett TJ, Schroth GP, Sun Y, Perera RJ. Integrated RNA and metabolite profiling of urine liquid biopsies for prostate cancer biomarker discovery. *Sci Rep.* 2020 Feb 28;10(1):3716.
- 106) Su ZT, Patel HD, Huang MM, Meyer AR, **Pavlovich CP**, Pierorazio PM, Javadi MS, Allaf ME, Rowe SP, Gorin MA. Cost-effectiveness Analysis of ^{99m}Tc-sestamibi SPECT/CT to Guide Management of Small Renal Masses. *Eur Urol Focus.* 2020 Feb 27. pii: S2405-4569(20)30067-5.

Inventions, Patents, Copyrights:

- 4/09 (filed) Provisional Patent; JHU Disclosure Ref. No. C-10673. "Benign Prostatic Hyperplasia (BPH) and Lower Urinary Tract Symptoms (LUTS) Biomarker and Therapy"; Investigators: Pavlovich CP, Fujita K, Parsons JK.

- 10/13 (filed) Invention Disclosure, Filed 10/13; JHU Disclosure Ref. No. C-12757. "Urine Biomarker Profile to Detect Prostate Cancer"; Investigators: Veltri RW, Christudass CS, Pavlovich CP, Partin AW.
- 3/18 (filed) Invention Disclosure, Filed 3/18; JHU Disclosure Ref. No. C-15195. "Prostate cancer detection and risk stratification by urine cytology in conjunction with RNA detection in situ"; Investigators: Luo, J, Pavlovich CP, Isaacs WB, Eskra JN. 20%

Extramural Funding:

Grants:

Current

Previous

4/1/05-3/31/10 *Prostate Cancer Detection by Molecular Urinalysis*
PC041214 Physician Research Training Award (PRT)
Dept. of Defense (DOD) Prostate Cancer Program
\$699,925 over 5 years (Total direct cost); Current year direct cost: \$129,616
Role: PI; (10% effort); Project goals: To develop and study various urinary assays for prostate cancer and assess their sensitivity and specificity for cancer detection, staging, and prognostication. A portion of this grant was also intended for education of the P.I. in molecular biology, biostatistics, and biomarker analysis.

7/1/05-6/30/10 *Prostate Cancer Detection by Molecular Urinalysis*
1K23DK071262-01, NIH/NIDDK
~\$700,000 over 5 years (Total direct cost); Current year direct cost: \$124,750
Role: P.I.; (50% effort); Project goals: Similar as those stated above, with the exception that urinary assays for the detection and prognostication of nonmalignant diseases of the prostate (BPH, chronic prostatitis/chronic pelvic pain syndrome) were also studied.

1/18/10-1/17/11 *Prostate Cancer Detection by Molecular Urinalysis*
3K23DK071262-05S1 American Recovery and Reinvestment Act
\$54,000 (Total direct cost)
Role: P.I.; A competitive continuation of K grant 1K23DK071262-01, NIH/NIDDK, used for post-doc salary support.

Overlap- Extramural Awards PC041214 and 1K23DK071262 overlapped significantly. The DOD and NIH desired to fund both projects despite the award overlap, so arranged with me to provide salary support to me and another co-investigator whom I chose at Hopkins, and who also trained in biomarker development via this Physician Training Grant. That co-investigator and I fulfilled the grant's scientific and training portions together. Overall, 60% of my effort went toward these grants during the 2005-2010 time period and they resulted in 6 publications.

Contracts:

Current

- 7/19 – present *A randomized phase 3 open-label trial of sipuleucel-T in active surveillance of prostate cancer*
Dendreon, Inc: Multi-institutional Clinical Trial
\$ TBD
Role: Site P.I. Project Goals: To determine if an autologous vaccine for prostate cancer can delay progression of prostate cancer during active surveillance
- 9/14 – 8/19 *Phase II Randomized, Placebo-Controlled Trial of PROSTVAC (PSA-TRICOM) in Patients with Clinically Localized Prostate Cancer Undergoing Active Surveillance*
NCI; Multi-institutional prostate cancer vaccine trial
\$220,000 over 5 years (Total contract, approximate)
Role: Site P.I. (1.5% effort); Project Goals: To determine whether a PSA-based prostate vaccine will induce potentially beneficial changes in the prostate glands of men with low risk clinically localized prostate cancer.
- Previous**
- 2/17-2/18 *TULSA-PRO RCT (TACT Trial) for clinically localized prostate cancer.*
Profound Medical; MRI-guided transurethral ultrasound ablation of prostate
\$ per patient accrued, arranged through Kimmel Cancer Center at Johns Hopkins
Role: Site P.I.
- 1/14 - 1/17 *High-resolution Ultrasound and the Detection of Prostate Cancer*
Imagistx, Inc.; Multi-institutional Industry-sponsored clinical trial
\$160,000 over 3 years (Total contract, approximate)
Role: Overall multi-institutional P.I. and local P.I.; (15% effort); Project Goals: To assess whether high resolution transrectal ultrasound is more effective at detecting clinically significant prostate cancer than conventional transrectal ultrasound. Trial designed by P.I. in consultation with sponsor.
- 7/1/12 - 3/31/13 *Multiplex serum-based biomarker assay for prostate cancer using RFID p-Chips*
SBIR-I PharmaSeq Inc. NCI Contract 2012-2013, P.I. Robert Veltri, PhD
\$30,865 (Total contract)
Role: Co-investigator; Project Goals: This Phase I proposal addresses NCI Topic 309, and is aimed at the development of an efficient, cost effective, serum-based multiplex assay for an early detection clinically significant prostate cancer panel.
- 7/1/10-6/30/12 *Prostate imaging by high-resolution ultrasound*
Imagistx, Inc.; Investigator-initiated clinical trial
\$130,738 (Total contract)
Role: P.I.; (20% effort); Project Goals: To determine if high-resolution ultrasound can identify prostate cancers in men scheduled for radical prostatectomy – histologic/imaging correlation study. Study design by P.I.
- 3/1/06-3/1/08 *Effect of Viagra on Return of Erectile Function after Nerve-sparing Laparoscopic Radical Prostatectomy*
Pfizer Inc.; Investigator-initiated clinical trial
\$75,000 over 2 years (Total contract)

Role: P.I.; (5% effort); Project goals: To study in double-blind placebo-controlled fashion whether sildenafil used prn vs. nightly for a year after nerve-sparing laparoscopic radical prostatectomy will aid in the recovery of erectile function and sexual quality of life. Trial design by P.I.

8/15/05-2/14/07 *Toremifene for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia*
GTx; Multi-institutional Industry-sponsored clinical trial
\$7,543 (Total contract)
Role: Site P.I.; (3% effort)

Intramural Funding:

Grants:

Current

Previous

9/1/18-8/31/19 *The Detection of High Grade Prostate Cancer Cells in Urine by RNA in-situ hybridization (RISH)*
The Irene and Bernard L. Schwartz Scholar
Patrick C. Walsh Prostate Cancer Research Fund
Total direct cost: \$100,000/yr
Role: P.I.

4/1/07-3/31/09 *Specific Detection of Prostate Cancer in Urine by Multiplex Immunofluorescence and Telomere FISH*
Patrick C. Walsh Prostate Cancer Research Fund, P.I. Alan Meeker Ph.D.
Total direct cost: \$75,000/yr
Role: Co-investigator; (5% effort)

11/1/10-11/1/11 *Characterization of the MCP-1(CCL2):CCR2 pathway in BPH and LUTS, and inhibition of this pathway in an animal model of chronic inflammation/BPH*
George M. O'Brien Center Pilot Program for Benign Prostate Hyperplasia/LUTS Research
\$50,000 (Total direct cost)
Role: P.I. (5% effort)

3/1/14 – 3/1/15 *Multiplex testing combining the Genetic Score Index (GSI) with the Prostate Health Index (PHI) for the detection of clinically significant prostate cancer*
Septembeard/David Koch Foundation
Total contract: \$25,000
P.I. William Isaacs, Ph.D.
Role: Co-investigator (5% effort)

Active Clinical Protocols/Trials

J18116 – Neoadjuvant dupilumab in men with localized high-risk prostate cancer –open label phase II
Co-I
PI – Pienta
8/19 – present

J1693 – Neoadjuvant enoblituzumab (MGA271) in men with localized intermediate and high-risk prostate cancer

Co-I

PI – Antonarakis

10/16 - present

J15179 - Phase I Study of Neoadjuvant Nivolumab in Patients with Non-metastatic High-risk Clear Cell Renal Cell Carcinoma

Co-I

PI –Allaf

9/15- present

EA8143 A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)

Co-I

PI – Carducci

5/17- present

J6151 A phase II study of definitive therapy for newly diagnosed men with oligometastatic prostate cancer after prostatectomy

Co-I

PI – Pienta

2/17 – present

S1802 Phase III Randomized Trial of Standard Systemic Therapy (SST) versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer

Co-I

Site PI – Gorin

12/18 – present

EDUCATIONAL ACTIVITIES

Educational Publications:

Peer Reviewed Publications:

Invited Review Articles:

- 1) **Pavlovich CP**, Schlegel PN: Cost-effectiveness of treatments for male infertility: A review. *Asst Repr Rev* 1998; 8 (1): 40-46.
- 2) Phillips JL, **Pavlovich CP**, Walther MM, Ried T, Linehan WM: The genetic basis of renal epithelial tumors: advances in research and its impact on prognosis and therapy. *Curr Opin Urol* 2001; 11(5): 463-469.
- 3) **Pavlovich CP**, Schmidt LS, Phillips JL: The genetic basis of renal cell carcinoma. *Urol Clin N America*, Aug 2003; 30(3):437-54.
- 4) **Pavlovich CP**, Schmidt LS: Searching for the hereditary causes of renal-cell carcinoma. *Nat Rev Cancer* 2004; 4(5): 381-93.
- 5) **Pavlovich CP**: Clinical Practice Point - “Does preservation of the neurovascular bundle affect surgical outcome in men with prostate cancer?” *Nat Clin Pract Urol* 2005; 2(3):124-5.

- 6) Hyndman ME, Mullins JK, **Pavlovich CP**: Pelvic node dissection in prostate cancer: extended, limited, or not at all? *Curr Opin Urol*. 2010; 20(3):211-7
- 7) Tosoian JJ, Ross AE, Sokoll LJ, Partin AW, **Pavlovich CP**: Urinary Biomarkers for Prostate Cancer. *Biomarkers in Urologic Cancers issue*. *Urol Clin N Am* 2016; 43(1): 17-38.
- 8) **Pavlovich CP**, Rocco B, Druskin SC, Davis JW. Urinary continence recovery after radical prostatectomy - anatomical/reconstructive and nerve-sparing techniques to improve outcomes. *BJU Int*. 2017; 120(2): 185-196.
- 9) Semerjian A, **Pavlovich CP**. Extraperitoneal Robot-Assisted Radical Prostatectomy: Indications, Technique and Outcomes. *Curr Urol Rep*. 2017 Jun;18(6):42. PMID: 28417427
- 10) Eskra JN, Rabizadeh D, **Pavlovich CP**, Catalona WJ, Luo J. Approaches to urinary detection of prostate cancer. *Prostate Cancer Prostatic Dis*. 2019 Sept 22(33): 362-381.

Editorials:

- 1) **Pavlovich CP**: Invited editorial comment re: “Kidney function following nephrectomy for renal cell cancer”. *Urology* 2004; 64 (1), 48.
- 2) **Pavlovich CP**: Invited editorial Comment re: “Small Renal Tumors” *J Urol* 2007; 178(2), 416-17.
- 3) Levinson AW and **Pavlovich CP**: Invited editorial comment re: “Prognostic Factors for Renal Cell Cancer with Tumor Thrombus Extension” *J Urol* 2007; 178(4), 1195.
- 4) **Pavlovich CP**: Invited editorial comment re: “Does obesity affect the costs of partial and radical nephrectomy?” *J Urol* 2007; 179(5), 1717-1718.
- 5) **Pavlovich CP**: Invited editorial comment re: “The Value of Preoperative Needle Core Biopsy for Diagnosing Benign Lesions Among Small, Incidentally Detected Renal Masses” *J Urol* 2008; 180(4), 1261.
- 6) **Pavlovich CP**: Invited editorial comment re: “External Validation of the Mayo Clinic Cancer Specific Survival Score in a Japanese Series of Clear Cell Renal Cell Carcinoma” *J Urol* 2008; 180 (4), 1295-1296.
- 7) **Pavlovich CP**, Carter HB: Invited editorial comment re: “The Impact of Serial Prostate Biopsies on Sexual Function in Men on Active Surveillance for Prostate Cancer.” *J Urol* 2012; Oct 188(4), 1258.
- 8) **Pavlovich CP**, Kaye D, Bivalacqua TB: Editorial response re: “Urinary outcomes are significantly affected by nerve-sparing quality during radical prostatectomy” *Urology* 2013, 82(6), 1354.
- 9) **Pavlovich CP**: Invited editorial comment re: Molinari et al. “Is ureteral stent placement by the transurethral approach during robot-assisted radical prostatectomy an effective option to preoperative technique?” *J Endourol*, 2014.
- 10) **Pavlovich CP**: Invited editorial comment re: “Reflex PCA3 mRNA Testing: Validation of Post-Biopsy Urine Samples and Correlation with Prostate Biopsy Findings in ~2000 Patients” *Urology*, 2014; 84(5): 1177-8.
- 11) **Pavlovich CP**: Invited editorial comment re: “Descriptive Technique and Initial Results for Robotic Radical Perineal Prostatectomy “ *Urology*, 2016; Jun 28 (ePub ahead of print).
- 12) Patel HD, **Pavlovich CP**: Invited Editorial Comment re: *J Urol*. 2016 Oct;196(4):1006-7.
- 13) **Pavlovich CP**: Invited editorial comment for www.practiceupdate.com/urology re: The Risk of Urinary Retention Following Robot-Assisted Radical Prostatectomy and its Impact on Early Continence Outcomes by Alnazari M. et al. 2018.
- 14) **Pavlovich CP**: Invited editorial comment re: *J Urol* April 2018 Cystic Renal Cell Carcinoma: A Report on Outcomes of Surgery and Active Surveillance in Patients Retrospectively Identified on Pretreatment Imaging, Kashan M et al. p.281.
- 15) Gupta M, **Pavlovich CP**: Invited Expert Commentary Re: Active Surveillance Magnetic Resonance Imaging Study (ASIST): Results of a Randomized Multicenter Prospective Trial. *Eur Urol*. 2019 May;75(5):876.

- 16) **Pavlovich CP:** Invited Editorial – Is Pelvic Lymph Node Dissection Necessary During Cytoreductive Radical Prostatectomy? *Eur Urol Oncol.* 2019 Sep;2(5):549-550.
- 17) **Pavlovich CP:** Invited Comment On “Effect of bladder neck sparing at robot-assisted laparoscopic prostatectomy on postoperative continence rates and biochemical recurrence by Preisser F et al.” in *Urologic Oncology, 2019 - Practice Patterns in Urology 2019.*
- 18) **Pavlovich CP:** Invited Comment On “ Single-Port Robot-Assisted Laparoscopic Radical Prostatectomy: Initial Experience and Technique With the da Vinci® SP Platform.” By Dobbs RW et al. in *BJUI, 2020 - Practice Patterns in Urology 2020.*

Case Reports:

- 1) **Pavlovich CP, Battiwalla M, Rick ME, Walther MM.** Antibody induced coagulopathy from bovine thrombin use during partial nephrectomy. *J Urol* 2001; 165: 1617.
- 2) Leach FS, Gutierrez ME, **Pavlovich CP, Wilson WH.** Lymphoma of the kidney; a case of mistaken identity, *Infections in Urology* 2001; 14(2), 46-48.
- 3) Wood BJ, Grippo J, **Pavlovich CP.** Percutaneous radiofrequency ablation for hematuria. *J Urol* 2001; 166: 2303-2304.
- 4) Ong AM, Bhayani SB, **Pavlovich CP.** Trocar Site Recurrence After Laparoscopic Nephroureterectomy. *J Urol* 2003; 170(4):1301.
- 5) Rogers CG, Epstein JI, **Pavlovich CP.** Adenofibroma of the testis discovered at exploration for torsion after trauma. *J Urol* 2003; 170(5): 1943.
- 6) Margreiter M, Hernandez DJ, Lang EK, **Pavlovich CP.** Horseshoe Kidney with Giant Hydronephrosis secondary to Ureteropelvic Junction (UPJ) Obstruction. *J Urol* 2010;183(1):329.
- 7) Gupta AD, Semins MJ, Marx JK, **Pavlovich CP.** Renal Artery Pseudoaneurysm After Partial Nephrectomy. *J Urol* 2010; 183(6):2390-1.
- 8) Alam R, Johnson MH, Caldwell T, **Pavlovich CP, Bivalacqua TJ, Tosoian JJ:** Diagnosing and Treating Inflammatory Myofibroblastic Tumor of the Bladder. *Case Rep Urol.* 2016; 5724020.
- 9) Doshi A, Manka MG, **Pavlovich C, Auster M.** Hidden Renal Artery Pseudoaneurysm: The Need for Repeat Angiographic Intervention in a Symptomatic Patient. *Urol Case Rep.* 2017 Mar 22; 12: 54-55. PMID:28352517

Letters, correspondence:

- 1) **Pavlovich CP, Pitts WR Jr:** (Letter) Re: Osteoporosis after orchiectomy for prostate cancer. *J Urol* 1999; 162 (4): 1392.
- 2) **Pavlovich, CP:** Guided energy treatments for renal tumor ablation. October, 2000. *AUA News.*
- 3) Levinson AW, Ward NT, **Pavlovich CP:** (Letter) Re: Defining potency: a comparison of the International Index of erectile Function short version and the Expanded Prostate Cancer Index Composite. *Cancer* 2009; 115(23): 5608.

Book chapters, Monographs:

- 1) **Pavlovich CP, Schlegel PN:** Male infertility – Current treatments, costs, and effectiveness, *AUA Update Series* 1999, Volume XVIII, Lesson 22.
- 2) **Pavlovich CP, Linehan WM, Walther MM:** Partial Adrenalectomy in Patients with Multiple Adrenal Tumors, *Curr Urol Rep* 2001; 2(1); 19-23.

- 3) **Pavlovich CP**, Walther MM: “Partial Adrenalectomy: Indications and Technique”. In Renal and Adrenal Tumors – Biology and Management, Eds. A. Belldegrun and E.D. Vaughan, Jr., Oxford University Press, Oxford, England, 2003: Chapter 58, 581-584.
- 4) **Pavlovich CP** and others: “Familial Renal Cell Carcinoma” chapter in WHO Classification of Tumours -Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs, 2004. Eds. Eble, Sauter, Epstein, Sesterhenn. IARC Press, Lyon, France.
- 5) **Pavlovich CP**, Schmidt L: “Hereditary Syndromes of Renal Cell Carcinoma” chapter in Cancer Hereditario textbook (Spanish), 2006. Sociedad Espanola de Oncologica Medica (SEOM) (www.seom.org). pp. 531-562. Updated, 2010.
- 6) Wagner AA, **Pavlovich CP**: “Laparoscopic Radical Cystectomy and Urinary Diversion”, chapter 25 in Atlas of Laparoscopic Urologic Surgery, 2007. Eds. J. Bishoff and L.R. Kavoussi: Saunders, Philadelphia, pp. 282-296.
- 7) **Pavlovich CP** and Reese AC: Chapter 6 - “Robot-assisted radical prostatectomy: A surgical guide to the extraperitoneal approach” in Radical Prostatectomy: Surgical Perspectives, 2014. Eds. J. Eastham and E.M. Schaeffer: Springer, New York, pp. 89-105.
- 8) **Pavlovich CP**, Gorin MA, Pierorazio PM, Mullins JK: “Pelvic lymphadenectomy for prostate and bladder cancer” chapter 8 in Pelvic Cancer Surgery: Modern Breakthroughs and Future Advances, 2014. Eds H Patel H, T Mould, J Joseph, C Delaney: New York, Springer-Verlag, pp 57-68.
- 9) Guo CC, Smith AK, **Pavlovich CP**:” Familial Forms of Renal Cell Carcinoma and Associated Syndromes” chapter in The Kidney: A comprehensive guide to diagnosis and management, 2015. Eds DE Hansel, C Kane, G Paner, and SS Chang: New York, Springer.
- 10) **Pavlovich CP**: “The Technique of Robotic Nerve sparing Prostatectomy: Extraperitoneal Approach” chapter in Prostate Cancer: Science and Clinical Practice, 2nd edition, 2015. Eds. J. Mydlo and C. Godec: Elsevier, San Diego, CA.

Books, textbooks: None

Other media:

- 1) Video: “Nerve-sparing During Laparoscopic Radical Prostatectomy: Adhering to the High Standard of Open Surgery” by Link RE, **Pavlovich CP**, Bhayani SB, Sullivan W, and Su L-M. Presented at American Urological Association Annual Meeting, 2004 (First Prize winner).

Teaching:

Classroom instruction:

- | | |
|--------------|---|
| 2001-2004 | Annual lecture to Urology residents and medical students at Urology Grand Rounds - Chapter Review, Johns Hopkins Hospital: Renal cell carcinoma |
| 2001-present | Annual lecture and coordination of didactic topics at Urology Grand Rounds, Johns Hopkins Hospital: Various topics (e.g. Laparoscopy, Adrenal) |

Clinical instruction:

- | | |
|--------------|---|
| 2001-present | Urology Service, Lead attending rounds once a week. |
|--------------|---|

CME instruction:

- | | |
|----------------|--|
| 11/23/02 | Urology Update: “Prostate Cancer Detection by Molecular Urinalysis,” Baltimore, MD. |
| 2/15/03 | Department of Surgery Grand Rounds address at Johns Hopkins Hospital: “Hereditary Renal Cell Carcinoma,” Baltimore, MD. |
| 12/13-12/15/03 | American Urological Association Course: “Advanced Laparoscopy”; Surgical laboratory preceptor (animal and cadaveric surgery); Lecture: “Ablative Technologies,” Baltimore, MD. |

- 9/22/05 “Update on Renal Cell Carcinoma”; Lecture: “The *Genesis* of Renal Cell Carcinoma”
Johns Hopkins Medicine, Baltimore, MD
- 11/06 Urology Update: “Urinary Markers for Prostate Cancer,” Baltimore, MD.
- 5/22/07 American Urological Association Conference Course, “Principles of Laparoscopic Oncologic Surgery,” Faculty. Course Director: Louis Kavoussi, MD. Anaheim, CA
- 5/10/07 “Update on Renal Cell Carcinoma”; Lecture: “Surgical Management of Renal Cell Carcinoma”. Johns Hopkins Medicine, Baltimore, MD.
- 12/17/08 Dept. of Surgery Resident Teaching Conference, Lecture: “Contemporary Approaches to Radical Prostatectomy,” Johns Hopkins Bayview Medical Center, Baltimore, MD.
- 11/8/08 Urology Update: “Penile Rehabilitation after Minimally-Invasive Radical Prostatectomy: Results from a Randomized Trial,” Baltimore, MD.
- 5/23/12 American Urological Association Conference Course: “How to Perform Extraperitoneal Robotic and Laparoscopic Surgery,” Faculty. Course Director: Jean Joseph, MD. Atlanta, GA.
- 8/2-3/12 Advanced Robotic Urologic Oncology and Prostate Cancer Update 2012, Faculty. Three Lectures: 1) Genetics of Prostate Cancer, 2) Urinary Biomarkers, 3) The PSA Screening Controversy
Course Director: Vipul Patel, MD. Napa, CA.
- 1/21-23/13 Advanced Robotic Techniques in Urology, Faculty. Performed live extraperitoneal robotic radical prostatectomy. Lectured on 1) Female Cystectomy, 2) Prostate Cancer Genetics, and 3) Moderated sessions and labs.
Course Directors: Vipul Patel, MD, Mr. Senthil Nathan. Chitra Sethia Centre for Robotics and MAS, UCH Education Centre, London, UK.
- 5/7/13 American Urological Association Conference Course: 072PG “Extraperitoneal Robotic and Laparoscopic Surgery: A step by step approach,” Faculty. Course Director: Jean Joseph, MD. San Diego, CA.
- 5/5/13 Address at *Korean World Urologic Congress (KWUC)* at AUA, “Selection criteria for Active Surveillance,” San Diego, CA.
- 10/18-19/13 Oncology Imaging of the Abdomen: Diagnosis, Staging and Management, CME Symposium, Faculty. Lectures: “Renal Masses: Radiologic Findings of Clinical Importance to the Treating Urologist” and “The Small Renal Mass: Modern Techniques in Evaluation and Treatment.” Course Director: Elliot Fishman, MD. Las Vegas, NV.
- 11/1-2/13 Advanced Robotic Surgery for the Urological Oncology Patient, Faculty. Lectures – “Extraperitoneal Robotic Prostatectomy: Step-by-step video” and “Robotic Cystectomy Outcomes and Cystectomy Considerations in Female Patients.” Course Director: Mohamad Allaf, MD. Johns Hopkins Hospital, Baltimore, MD.
- 5/15/17 American Urological Association Conference Course: 066IC “Extraperitoneal Laparoscopic and Robotic Urologic Surgery” Faculty. Course Director: Jean Joseph, MD. Boston, MA.
- 9/15 – 9/16/17 AUA MOC Recertification Review Course: Oncology – General Overview, Adrenal Cancer, Kidney Cancer (3 lectures)

Workshops/seminars: *See above under “CME instruction”*

Mentoring:

Advisees:

- 2001-2007 *Advanced Laparoscopy fellows*: Co-mentored by Li-Ming Su, M.D. and me every year consecutively Tom Hsu, M.D., Sam Bhayani, M.D., Richard Link, M.D. Ph.D., Andrew Wagner, M.D., Aaron Sulman, M.D., Adam Levinson, M.D.
- 2002-2003 Mark Gonzalgo, M.D., Ph.D., Resident: Spent one year doing clinical and laboratory research in part under my supervision (and under the primary laboratory tutelage of Dr. William G. Nelson).
- 2003-2004 Craig Rogers, M.D., Resident: Spent one year doing clinical and laboratory research under my supervision (and under the primary laboratory tutelage of Dr. William G. Nelson).
- 2003 Summer Marian Grade, German medical student: Spent Summer 2003 in my lab.
- 2004 Summer Will Dahl, JH Student: Spent Summer 2004 in my lab.
- 2006-2008 Kazutoshi Fujita M.D., Ph.D., Postdoctoral fellow, urologist: Spent 2 years in my laboratory within the Brady Urological Research Labs.
- 2007 - Present *Urologic Oncology fellows*: Co-mentored by me as Fellowship Program Director with other Hopkins urologic oncologists from 2007-present, each for 2 year periods (Thomas Guzzo, M.D., M. Eric Hyndman, M.D., Ph.D., Adam Reese, M.D., Jen-Jane Liu, M.D., Michael Johnson, M.D., C.J. Stimson, M.D. J.D., Alice Semerjian M.D., Mohit Gupta, M.D. (current fellow), Max Kates (current fellow).
- 2009 Summer Brian Lin, JH medical student and Persky fellow (intramural Urology scholarship for Summer research, 2009) under my tutelage.
- 2016-2017 Sarah Collica, JH Medical student, mentored a clinical research project.
- 2017-present Daniel Rabizadeh, JH Undergraduate, mentored an ongoing laboratory research project with Jun Luo, PhD.
- 2019 Summer Zhao Tony Su, JH Medical Student and Persky Fellow (intramural Urology scholarship for Summer research, 2019) under my tutelage.

Thesis Committees: None

Training Grant Participation: None

Educational Program Building/Leadership:

- 2009 – Present Fellowship Program Director, Urologic Oncology Fellowship, James Buchanan Brady Urological Institute, Department of Urology, Johns Hopkins University School of Medicine.
- 2014 As Fellowship Director, applied for, and obtained Society of Urologic Oncology (SUO) 5-year accreditation for the Johns Hopkins Urologic Oncology fellowship. SUO accreditation has raised the national stature of the two-year JH Urologic Oncology fellowship.
- 2019 Obtained full reaccreditation for the SUO fellowship for another period of 5 years

Educational Extramural Funding

- 2012 – Present **\$1,000,000 Endowment:** As Fellowship Director, participated in obtaining funding for the Urologic Oncology Fellowship at the Johns Hopkins University School of Medicine. The above endowment was obtained through the philanthropy of the Warburton Family and Dr. Hugh Judge Jewett, both of whom had developed a close relationship with Dr. Patrick C. Walsh (former chair of Urology) and who jointly

2013-2018 endowed the ongoing two-year “Warburton Family Foundation and Hugh Judge Jewett Fellowship in Urologic Oncology”.
\$100,000 Grant: As Fellowship Director, obtained a C. R. Bard Foundation grant to support the Urologic Oncology Fellowship, Brady Urological Institute at the Johns Hopkins University School of Medicine. This grant, to be distributed over 5 years, was obtained by applying to Bard Pharmaceutical for support of the fellowship. Lisa Hammann (Office of Development) and I co-wrote the grant application and were awarded the funding in 2013.

CLINICAL ACTIVITIES

Certification:

- Medical Licensure: State of Maryland, #D0056487
- Medical Licensure: Washington D.C. (2014 – pending)
- Medical Boards: NBME certified 1994 (passed NBME I, USMLE II, and NBME III)
- Specialty Board: Board certified in Urology, 2003; re-certified in 2013.

Clinical (Service) Responsibilities:

2001-present Urology Service, Johns Hopkins Bayview Medical Center. Attending physician. On-call every Tuesday (24 hours) and every fourth weekend (Friday morning through Monday morning, 72 hours).

Clinical Program Building/Leadership:

2001-present Along with Dr. Li-Ming Su initiated the first minimally-invasive radical prostatectomy technique-and-outcomes program (and website) at JHMI.
2004-present Along with Joseph Herman, MD (Radiation Oncology), and Fariba Asrari, MD (Radiation Oncology), started the first Multi-Disciplinary Prostate Cancer Clinic offered by JHMI, initially at the Johns Hopkins Greenspring Radiation Oncology Clinic then at the Urology Clinic at White Marsh (2004-2007). Currently, participate as attending physician approximately once a month in the ongoing Multi-Disciplinary Prostate Cancer Clinic at Johns Hopkins Hospital’s Department of Radiation Oncology.
2009 Assisted Johns Hopkins Bayview Medical Center in obtaining Commission on Cancer (CoC) Comprehensive Cancer Center Accreditation in 2009. Enrollment of urologic oncology patients enrolled in my clinical trials at Bayview was instrumental to achieving this important designation for the facility, as without these trial patients we would not have achieved the necessary target percent enrollment in clinical trials.
2019 Plan to start a Hereditary Prostate Cancer Clinic and be its Director, with support from the Department and the Patrick C. Walsh Research Fund

Clinical Extramural Funding: None

SYSTEM INNOVATION AND QUALITY IMPROVEMENT ACTIVITIES

11/12 Visit to Kuwait with Dr. Mohamad Allaf, JHU Urology, to advise, lecture, and operate. Arranged through JH International.

ORGANIZATIONAL ACTIVITIES

Institutional Administrative Appointments:

- 2000-2001 NIH Fellows Committee - Representative, Urologic Oncology Branch (as fellow)
2001 NIH Fellows Symposium: Reviewer of abstracts, NIH (as fellow).
2000-2002 NIH-HHMI Research Scholars Program - Reviewer of applications (as fellow).
2001-2006 Credentials Committee - Member, Johns Hopkins Bayview.
2003- present Cancer Committee, Johns Hopkins Bayview -
 ▪ 2003-2007: Cancer Liason Physician, Johns Hopkins Bayview
 ▪ 2007- present: Member
2007 – present Surgical Value Analysis Task Force - Co-Chair, Johns Hopkins Bayview.
2009 – 2013 Medical School Faculty Senate, Johns Hopkins University School of Medicine -
 Representative, elected to two consecutive terms

Editorial Activities:

Editorial Board:

- *Case Reports in Urology* (2013-2017)
- *British Journal of Urology International* (2017-present)

Journal peer-review activities:

Asian Journal of Andrology
British Journal of Cancer
British Journal of Urology
Current Urology Reports
European Urology
Journal of Clinical Investigation
Journal of Endourology
Journal of the National Cancer Institute
Journal of Urology
Nature Reviews Urology
Prostate Cancer and Prostatic Diseases
Sensors
Urology
Urologic Oncology
World Journal of Urology

Advisory Committees, Review Groups/Study Sections:

- 8/05 Grant Review for Prostate Cancer Research Program 2005, Dept of Defense, Reston VA (Physician Research Training Grants).
8/06 Grant Review for Prostate Cancer Research Program 2006, Dept of Defense, Reston VA (Physician Research Training Grants).
9/08 Grant Review for Prostate Cancer Research Program 2008, Dept of Defense, Reston VA (Clinical Trials).
12/09 FDA General Issues Panel Meeting: “Clinical Studies of Devices Intended for the Treatment of Localized Prostate Cancer,” Gaithersburg, MD
6/10-12/13 FDA Medical Devices Advisory Committee Member- Gastroenterology and Urology Devices, Voting Member.
Participated in eight FDA drug or device advisory panels during this term (3 yr-Term).
01/14-present FDA Advisory Panel *ad hoc member* (Oncology, Endocrinology and Metabolism)
03/16-12/18 SUO Urologic Oncology Fellowship Committee
01/16-08/17 DSMB Member for Procept Surgical’s BPH clinical trial, “The Water Study”
01/17-08/18 DSMB Member for Procept Surgical’s BPH clinical trial, “The Water II Study”

- 2017-2021 FDA Bone, Reproductive, and Urologic Drugs Advisory Committee Member (BRUDAC), Voting Member.
- 2018 - present Steering Committee Member, ProVent multi-institutional clinical trial for prostate cancer patients in active surveillance, Dendreon, Inc.
- 2018 - present Verb/Ethicon Global Clinical Advisory Board for Urology, Member

Professional Societies:

- 1999-2007 American Medical Association (AMA) - Active member
- 2003-present American Urological Association (AUA) - Active member
- 2002-present Mid-Atlantic Section, American Urological Association (MA-AUA) – Active member
- 2001-present Society of Urologic Oncology (SUO) - Active member
- 2007-present Society of Endourology - Active member
- 2013-2016 MA-AUA Board of Directors

Conference Organizer, Session Chair:

- 2004 Society of Urologic Oncology Winter Meeting, Bethesda: Poster Judge.
- 2005 Society of Urologic Oncology Winter Meeting, Bethesda: Poster Judge.
- 2005 American Urological Association Annual Meeting, San Antonio: Co-Chair Kidney and Ureteral Cancer Basic Research Discussed Poster Session.
- 2006 Mid-Atlantic Section AUA, Washington DC: Poster Judge and Resident Award Presenter
- 2006 World Congress of Endourology, Cleveland: Poster Session Co-Moderator, Moderated Poster Session 27 “Laparoscopy/Robotics.”
- 2012 Society of Urologic Oncology Winter Meeting, Bethesda: Prostate Cancer Organizing Committee Member
- 2013 Society of Urologic Oncology Winter Meeting, Bethesda: Prostate Cancer Organizing Committee Member
- 2014 Mid-Atlantic AUA Session co-Moderator: “Complications during Robotic Urologic Surgery” – Baltimore, MD Sept 19, 2014
- 2020 12th Annual Symposium on Focal Therapy and Imaging 2020 – Session co-Moderator - Washington DC

Consultantships: None

RECOGNITION

Awards, Honors:

- 1984 National Presidential Scholar, United States Government.
- 1984 – 1987 Harvard College Scholarship, Harvard College.
- 1984 – 1987 Harvard National Scholarship, Harvard College.
- 1987 – 1988 Fulbright – Swiss Universities Grant, to study Molecular Biology in Geneva Switzerland under Ulrich Laemmlli, PhD.
- 1991 – 1992 Research Scholarship, Immunology, HHMI – National Institutes of Health under B.J. Fowlkes, PhD.
- 1992 – 1993 Continuing Scholarship Award, Howard Hughes Medical Institute (HHMI).
- 1993 Alpha Omega Alpha Honor Medical Society, Alpha Omega Alpha.
- 1997 Yamanouchi Prize for Urology Resident Research, Yamanouchi.
- 1998 First Prize - AUA Ambrose-Reed Socioeconomics Essay Contest (National award), “A cost analysis of treatment options for male infertility,” American Urological Association (first author).

- 1999 Distinguished Housestaff Award, New York Hospital – Cornell Medical Center.
- 1999 Outstanding Presentation, Society of University Urology Residents.
- 1999 Pfizer Scholar in Urology, Pfizer Pharmaceuticals, NY, NY.
- 1999 – 2001 Fellowship, National Institutes of Health Urologic Oncology Branch, American Foundation of Urologic Disease (A.F.U.D.).
- 1999 – 2001 Loan Repayment Award, National Institutes of Health.
- 2004 First Prize - AUA Ambrose-Reed Socioeconomics Essay Contest (National award), “Making ends meet: a cost comparison of laparoscopic and open radical retropubic prostatectomy,” American Urological Association (senior author).
- 2004 First Prize – AUA Video Contest: “Nerve-sparing Laparoscopic Radical Prostatectomy,” American Urological Association.
- 2006 Urology Residents’ Teaching Award, Brady Urological Institute, Johns Hopkins University School of Medicine
- 2012 Coffey-Krane Prize for Best Paper, British Journal of Urology International; “Impact of surgical technique (open vs laparoscopic vs robotic-assisted) on pathological and biochemical outcomes following radical prostatectomy: an analysis using propensity score matching” (senior author)
- 2013 Urology Residents’ Teaching Award, Brady Urological Institute, Johns Hopkins University School of Medicine
- 2014 Best Reviewer Award, *Journal of Urology*; presented at New Orleans AUA 2015
- 2017 Top Doctor Award: Prostate Cancer Surgery, *Baltimore Magazine*.

Invited Talks, Panels:

- 8/00 “Hereditary Renal Cell Carcinoma and the Birt-Hogg-Dubé Syndrome”- Urology Grand Rounds; Department of Urology, Memorial-Sloan Kettering Cancer Center, New York, NY.
- 10/00 “The Small Renal Mass” - Urology Grand Rounds; Department of Urology, University of Toronto, Toronto, Ontario, Canada.
- 10/00 “Current Approaches to Metastatic Renal-Cell Carcinoma” - Citywide Urology Dinner Grand Rounds; Department of Urology, University of Toronto, Toronto, Ontario, Canada.
- 10/02 “Management of Upper Tract Urinary Neoplasms” – Panelist, Mid-Atlantic AUA Conference, Baltimore, MD.
- 3/03 “Laparoscopic Radical Prostatectomy” - Society of Urologic Nursing, Baltimore, MD.
- 7/03 “Hereditary Renal Cell Carcinoma: New Developments” – Meet-the-Expert Sunrise Session, American Association of Cancer Research 2003, Washington, DC.
- 6/04 “Laparoscopic Radical Prostatectomy: Treatment Outcomes at Johns Hopkins” – Urology Grand Rounds, Washington Hospital Center, Washington, DC.
- 3/05 “Laparoscopic Radical Prostatectomy: Minimizing the Morbidities of Radical Surgery” – Noon Seminar, Roswell Park Cancer Institute, Buffalo, NY.
- 10/06 “Minimally Invasive Radical Prostatectomy Outcomes” – Panelist and Presenter, Mid-Atlantic Section AUA, Washington, DC.
- 6/09 “Contemporary Approaches and Outcomes of Radical Prostatectomy: 2009” – Prostate Cancer Support Group, Johns Hopkins Hospital Kimmel Cancer Center, Baltimore, MD.
- 10/09 “Extraperitoneal Access Techniques” – Plenary address, World Congress of Endourology. Part of “Laparoscopic Radical Prostatectomy: Tips and Tricks” session, Munich, Germany.

- 3/12 “Therapeutic Options in Radical Prostate Surgery” – General Session, Maryland Urologic Society Conference, Sinai Hospital, Baltimore MD.
- 10/12 “Robotic Radical Prostatectomy” - Society of Urologic Nursing, Baltimore, MD.
- 11/13 Two lectures on prostate diseases and male health, arranged through JH International. One to the students at St. Matthews Medical School, one to the community at the Lion’s Club (sponsor: Dr. Eli Timoll, MD), Grand Cayman, Cayman Islands.
- 3/14 6 Plenary lectures on various urologic oncology topics (e.g. “extraperitoneal robotic surgery” “active surveillance for prostate cancer”) at the Annual Meeting at the Hospital Universitario de la Fundación Santa Fé de Bogotá, Bogotá, Colombia.
- 3/14 “Robotic Surgery for Urologic Cancers” address at the Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS invited by Prof. Dino Amadori. Meldola (FC), Italy.
- 5/14 “The Incidental Renal Mass” –Medical Grand Rounds, DC Veteran’s Affairs Medical Center. Host: Medicine Department Chairman Charles Faselis, M.D., Washington, DC.
- 9/4-9/6/14 Three plenary lectures- “Robotic Partial Nephrectomy”, “Nervesparing robotic radical prostatectomy”, and “Laparoscopic advanced surgery: what changed after the robot?” at the Sao Paulo Urologic Society - XIII Congresso Paulista de Urologia, Sao Paulo, Brazil.
- 2/5/15 “The effects of neurovascular bundle sparing at radical prostatectomy: Improving surgical outcomes”. Guest speaker at Prostata Dialog I Trondheim, Scandic Nidelven, Havnegata 1-4, Trondheim, Norway.
- 3/26-3/27/15 5 Plenary lectures on various Urologic Oncology Topics at the Simposio 2015 “Fronteiras da Medicina” at the Hospital Moinhos de Vento in Porto Alegre, Brazil, a Johns Hopkins International Affiliate Institution.
- 6/12/15 “Extraperitoneal Robotic Radical Prostatectomy” at the Norwegian Prostate Cancer Symposium, Oslo, Norway. A Johns Hopkins Update.
- 8/26/15 “High-resolution TRUS Biopsy” presenter. UroTrack Meeting (a joint CME program between Harvard, Columbia, and Johns Hopkins), Boston, MA.
- 11/12/15 “High resolution ultrasound in Urology”, ESUI 2015 (European Society of Urological Imaging, Barcelona, Italy.
- 05/02/16 “Clinical experiences and new possibilities using micro-ultrasound for prostate cancer detection” Plenary Lecture, 10th International Conference, Ultrasonic Biomedical Microscanning (UBM 2016), Bonaire.
- 9/15-9/17/16 “Tips and Mishaps” co-presenter/moderator; “Extraperitoneal Radical Prostatectomy” presentation. UroTrack Meeting, Baltimore, MD.
- 3/31-4/1/17 “Clinical Experiences and New Possibilities for Targeted Prostate Biopsy using Micro-ultrasound” - Plenary Lecture at Virginia Urologic Society, Pentagon City, VA.
- 5/4-5/6/17 5 plenary lectures, one roundtable, and two session lectures – topics ranging from “Beyond PSA” to “Robotic pelvic lymph node dissection” to “Robotic radical prostatectomy”. Jornada Paulista de Urologia XV, Campos do Jordao, Brazil.
- 4/13-4/14/18 “Clinical Biomarkers and Imaging for Prostate Cancer Detection 2018” – Keynote speaker at Virginia Urologic Society, Norfolk, VA.
- 8/3-8/4/18 3 lectures and 2 panel sessions on prostate cancer issues, Simposio de Uro-Oncologia e Cirurgica Robotica do HCPA - Hospital Clinicas de Porto Alegre, Porto Alegre, Brazil.
- 10/5/18 Moderator, Prostate Cancer Moderated Poster Session, Mid-Atlantic AUA, Washington, DC.

- 3/29-3/31/19 3 invited talks at C2R Biennial Clinical:Research Conference – Guest Faculty – (Urine Cytology, Liquid Biomarkers, and a Case Presentation), Toronto, CA.
- 10/3/19 “Clinically Localized Prostate Cancer Guidelines” presentation. UroTrack Meeting, Baltimore, MD.

OTHER PROFESSIONAL ACCOMPLISHMENTS

- Established and now participates in a biorepository of urine samples for ongoing prostate cancer and prostatic disease biomarker research.
- Trained and experienced in minimally invasive approaches to urologic malignancy, including laparoscopic (laparoscopic radical prostatectomy, cystectomy, nephrectomy and partial nephrectomy), robotic, and ablative technologies.
- Certified in the use of the *Da VinciTM* robot (Intuitive Surgical, Sunnyvale, CA) for robot-assisted laparoscopic oncologic surgery (certificate, May 2003).
- Certified in extra-corporeal shock-wave and laser lithotripsy
- Coursework: Biostatistics 611 (Statistical Reasoning in Public Health I) for credit, Johns Hopkins Bloomberg School of Public Health, 2007 –received an “A”.
- Credentials up to date for Biosafety and Human Subjects Research at JHUSOM